Core Viewpoint - Aldebaran Resources Inc. has filed an updated Technical Report and Preliminary Economic Assessment for the Altar copper-gold project, indicating a strong economic outlook for the project with significant production potential and attractive financial metrics [1][3]. Group 1: Project Details - The Altar Preliminary Economic Assessment (PEA) has an effective date of September 1, 2025, and was prepared by SRK Consulting Inc. with Knight Piesold as a subcontractor [1]. - The PEA indicates a base case scenario with a Net Present Value (NPV) of US$2 billion and an Internal Rate of Return (IRR) of 20.5%, highlighting the project's long-term viability and profitability [3]. - Aldebaran holds an 80% interest in the Altar project, which is located in San Juan Province, Argentina, and is part of a cluster of world-class porphyry copper deposits [6]. Group 2: Joint Venture Update - Nuton Holdings Ltd., a venture of Rio Tinto, has terminated its option to joint venture agreement to acquire a 20% interest in the Altar project, citing a shift in focus to later-stage projects [2]. - Despite the termination, there remains the potential for a licensing agreement between Nuton and Aldebaran to utilize Nuton Technology at the Altar project [2]. Group 3: Management Commentary - The CEO of Aldebaran expressed confidence in the Altar project, emphasizing its significance for both the company and Argentina, and acknowledged Nuton's participation while understanding their strategic shift [3].

Core Viewpoint - Arvinas, Inc. announced that multiple abstracts on vepdegestrant (ARV-471), a novel investigational PROTAC estrogen receptor degrader, have been accepted for presentation at the San Antonio Breast Cancer Symposium (SABCS) scheduled for December 9-12, 2025, highlighting its potential as a treatment for advanced or metastatic breast cancer with ESR1 mutations [1][5][6] Presentation Details - The presentation titled "Subgroup analyses of VERITAC-2" will be led by Erika P. Hamilton, focusing on vepdegestrant versus fulvestrant in ER+/HER2- advanced breast cancer [2] - Another presentation will cover circulating tumor DNA biomarker analyses in a phase 1/2 study of vepdegestrant, presented by Seth A. Wander [2] - David Chandiwana will present on the real-world prevalence of ESR1 mutations among patients with ER+/HER2- metastatic breast cancer after first-line treatment [2] - Jo Chien will present on the I-SPY2 Endocrine Optimization Pilot trial evaluating vepdegestrant in combination with other therapies [2] About Vepdegestrant - Vepdegestrant is an orally bioavailable PROTAC estrogen receptor degrader that has shown statistically significant improvement in progression-free survival compared to fulvestrant in patients with ESR1-mutated advanced breast cancer [5] - The FDA is currently reviewing the New Drug Application (NDA) for vepdegestrant, with a Prescription Drug User Fee Act (PDUFA) action date set for June 5, 2026, and it has received Fast Track designation [5] Collaboration with Pfizer - Arvinas has a global collaboration with Pfizer for the co-development and co-commercialization of vepdegestrant, sharing worldwide development costs and profits [6] - In September 2025, both companies announced plans to select a third party for the commercialization and further development of vepdegestrant [6] Company Overview - Arvinas is a clinical-stage biotechnology company focused on developing protein degradation therapies through its PROTAC platform, targeting various diseases including advanced breast cancer [7] - The company is advancing multiple investigational drugs, including ARV-102 for neurodegenerative disorders and ARV-393 for non-Hodgkin lymphoma, alongside vepdegestrant [7]

Core Insights - Brunswick Exploration Inc. has identified Saudi Arabia as a highly prospective region for lithium exploration and has been awarded an exploration license, marking its first systematic exploration program in the country [1][2] - The exploration license covers an area of 8,467 hectares, located approximately 150 km from Buraydah and 450 km east of Riyadh, with favorable geological conditions for lithium [3][4] - Saudi Arabia is positioning itself as a major lithium processing hub as part of its Saudi Vision 2030 initiative, which aims to diversify its economy beyond oil and gas [5] Company Developments - The exploration license is pending final government approval, and the company is completing administrative requirements to begin exploration [3] - A prospecting campaign is planned to commence in the first half of 2026, allowing the company to generate results year-round by leveraging its expertise in lithium exploration [2] - The company is also advancing its projects in Canada and Greenland, with a maiden resource estimate for the Mirage project expected in early Q1 2026 [1][2] Industry Context - Saudi Arabia has a well-established mining history, supportive government policies, and strong funding for mining initiatives, making it an attractive jurisdiction for lithium exploration [4] - The region has seen little historical hard rock lithium exploration, presenting a significant opportunity for the company [4] - Prominent mining companies are actively exploring in Saudi Arabia, indicating a growing interest in the region's mineral resources [5]

Core Insights - Biomea Fusion, Inc. is a clinical-stage biopharmaceutical company focused on developing oral small molecule therapies for diabetes and obesity [2] - The company will participate in two upcoming investor conferences, providing opportunities for engagement with investors [1][4] Company Overview - Biomea Fusion is advancing therapies such as icovamenib, a selective menin inhibitor for diabetes, and BMF-650, a next-generation oral GLP-1 receptor agonist for obesity [2] - The company's mission is to deliver transformative treatments for patients with diabetes, obesity, and related conditions, addressing a significant global health challenge [2] Upcoming Events - Biomea will participate in the Piper Sandler 37th Annual Healthcare Conference on December 2, 2025, with a fireside chat at 8:00 AM (EST) and one-on-one meetings [4] - The company will also take part in the 8th Annual Evercore Healthcare Conference on December 3, 2025, with a fireside chat at 7:30 AM (EST) [4]

Core Insights - Pasithea Therapeutics Corp. announced positive safety, pharmacokinetic (PK), and pharmacodynamic (PD) data from Cohort 7 (37mg capsules) in its ongoing first-in-human trial for PAS-004, a macrocyclic oral MEK inhibitor targeting MAPK pathway-driven advanced solid tumors [1][2][8] Safety and Tolerability Results - Zero treatment-related adverse events were observed during the dose-limiting toxicity (DLT) period in Cohort 7 [1][6] - The Safety Review Committee recommended proceeding to the next dose level, Cohort 8 (45mg capsules), without modifications [1][6] Pharmacodynamics (PD) Results - PD data supports continuous suppression of the MAPK pathway throughout the 24-hour dosing cycle [1][2] - PAS-004 demonstrated an ability to inhibit phosphorylated extracellular signal-regulated kinase (pERK) at levels of 80% near Cmax and above 60% at Cmin [6] Pharmacokinetics (PK) Results - The PK profile showed linearity and dose-proportionality with a Cmax/Cmin ratio of less than 2 [1][6] - Achieved AUC of 6,690 ng·h/mL, Cmax of 313 ng/mL, and Cmin of 260 ng/mL [1][6] Company Overview - Pasithea is focused on developing PAS-004 for treating RASopathies, MAPK pathway-driven tumors, and other diseases, currently in Phase 1 clinical trials for advanced cancer and neurofibromatosis type 1 [8]

Core Insights - The initiation of the HELIOS registrational program represents a significant advancement in the treatment of diabetic retinal disease, with AXPAXLI potentially addressing the needs of over 6 million NPDR patients in the U.S. who currently receive minimal therapy due to treatment burdens [2][3] - The HELIOS-2 and HELIOS-3 trials are designed to evaluate the efficacy of AXPAXLI in treating non-proliferative diabetic retinopathy (NPDR) and aim for a broad diabetic retinopathy label, including patients with non-center-involved diabetic macular edema (non-CI-DME) [2][3][12] - AXPAXLI is expected to provide durable efficacy with less frequent dosing, which could significantly improve patient adherence and outcomes compared to current treatment options that require frequent injections [2][3][12] Company Overview - Ocular Therapeutix, Inc. is an integrated biopharmaceutical company focused on redefining the retina experience through innovative treatments for retinal diseases, including AXPAXLI, which is currently in Phase 3 clinical trials for wet AMD and NPDR [14][15] - AXPAXLI is a bioresorbable intravitreal hydrogel that incorporates axitinib, a multi-target tyrosine kinase inhibitor with anti-angiogenic properties, aimed at treating various retinal diseases [4][5] HELIOS Program Details - The HELIOS program consists of two complementary superiority studies: HELIOS-2 and HELIOS-3, which will assess the safety and efficacy of AXPAXLI in approximately 432 and 930 subjects, respectively, with moderately severe to severe NPDR [6][9] - Both studies utilize a novel ordinal diabetic retinopathy severity score (DRSS) as the primary endpoint, focusing on changes in severity at Week 52 from baseline [8][11] - HELIOS-2 compares AXPAXLI dosed every 12 months to ranibizumab, while HELIOS-3 evaluates different dosing regimens of AXPAXLI against sham treatment [7][10] Industry Context - Diabetic retinopathy is a prevalent condition affecting over 103 million people globally, with a significant portion of NPDR patients remaining untreated due to the burdensome nature of existing therapies [12][13] - The HELIOS trials aim to address the unmet need for effective treatments with durable efficacy, potentially transforming care for diabetic retinal disease and improving patient outcomes [3][12]

Core Insights - Sionna Therapeutics is focused on developing innovative treatments for cystic fibrosis (CF) by normalizing the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein [2][4] - The company is advancing a pipeline of small molecules aimed at correcting defects caused by the F508del genetic mutation, which is significant for improving clinical outcomes for CF patients [2] Company Overview - Sionna Therapeutics is a clinical-stage biopharmaceutical company dedicated to revolutionizing CF treatment through novel medicines that stabilize CFTR's nucleotide binding domain 1 (NBD1) [2] - The company aims to deliver differentiated medicines that restore CFTR function to near-normal levels, potentially enhancing the quality of life for individuals with CF [2] - Sionna is also developing a portfolio of complementary CFTR modulators designed to work synergistically with its NBD1 stabilizers [2] Investor Engagement - Sionna will participate in upcoming investor events, including the Annual Evercore Healthcare Conference on December 3, 2025, and the Citi 2025 Global Healthcare Conference on December 4, 2025 [4] - Live webcasts of these presentations will be available on Sionna's Investor Relations website, with replays accessible after the events [1][3]

Core Insights - HyOrc Corporation has entered into a Memorandum of Understanding (MOU) with Zero-Emission Locomotive Technologies (ZELTECH) and Dreamstar Lines to develop clean-energy locomotive solutions for the Los Angeles to San Francisco rail corridor [1][2][3] Group 1: Partnership and Collaboration - The MOU involves the use of next-generation clean-energy locomotives, including hybrid configurations powered by the HyOrc Rankine-cycle multi-fuel engine, exclusively authorized for U.S. locomotive applications by ZELTECH [2] - The collaboration aims to create a joint venture to develop, integrate, and commercialize hydrogen and multi-fuel locomotive repower systems for U.S. operators, leveraging California's zero-emission rail programs [3] Group 2: Executive Statements - Dreamstar Lines' President, Thomas Eastmond, emphasized the vision for cleaner and smarter transportation through this partnership [5] - ZELTECH's CEO, Tom Mack, highlighted the necessity for clean-power locomotives in California's railroads, stating that HyOrc's engine makes zero-emission locomotives achievable [5] - HyOrc's CEO, Reginald Fubara, noted the engine's high efficiency, reliability, and fuel flexibility, asserting that this collaboration accelerates the transition to clean commercial rail [5] Group 3: Company Developments - HyOrc Corporation has recently achieved effective Form-10 registration, making it a fully reporting public company under the Securities Exchange Act of 1934, which enhances its transparency and institutional readiness [5][6]

Core Insights - Village Farms International, Inc. and its subsidiary Rose LifeScience Inc. have launched Promenade's first vape product, Matin, marking a significant advancement in Quebec's regulated cannabis market [1][4] - The introduction of a regulated vape category in Quebec is expected to enhance consumer access and drive growth in the legal cannabis market [2][4] Company Overview - Village Farms is a large-scale, vertically-integrated supplier of high-value plant-based Consumer Packaged Goods, leveraging decades of experience in Controlled Environment Agriculture [6] - The company operates one of the largest cannabis operations globally through its subsidiary Pure Sunfarms, with 2.2 million square feet of greenhouse production capacity [7] - Village Farms also holds an 80% stake in Rose LifeScience, a leader in cannabis product commercialization in Quebec [7] Market Dynamics - Quebec accounts for 13% of national cannabis sales, generating $202 million in cannabis revenue in Q3 2025, reflecting a 10% year-over-year increase [4] - Recent consumer data indicates that 55% of cannabis consumers in Quebec are interested in purchasing vape products from legal channels, driven by safety and quality concerns [3] Product Details - The Promenade Matin vape is designed specifically for the Quebec market, featuring a blend of cannabinoids including THC and CBG, and is characterized by bright citrus notes and a smooth finish [5] - The product will be available across Quebec starting November 26, 2025 [5]

Insiders boost ownership to 8.8% as executives signal confidence in Newton’s growth outlookCAMARILLO, Calif., Nov. 24, 2025 (GLOBE NEWSWIRE) -- via IBN – Newton Golf Co. (OTCQB: NWTG) said Friday that senior executives and a board member purchased shares of the company’s stock on the open market following the release of its third-quarter results. The purchases were made by Chief Executive Officer Greg Campbell, Chief Financial Officer Jeff Clayborne and independent director Brett Hoge. In total, insiders bo ...